Lipocine Inc. Announces Successful Phase 1 Results With LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth

SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the successful completion of a Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate (HPC) product candidate. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers. - See more at: http://www.globenewswire.com/news-release/2014/05/15/636804/10081861/en/Lipocine-Announces-Successful-Phase-1-Results-With-LPCN-1107-Potentially-the-First-Oral-Product-for-the-Prevention-of-Preterm-Birth.html#sthash.3VqD75jW.dpuf

Help employers find you! Check out all the jobs and post your resume.